Portfolio company
Velorum Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops heme-sequestering biologic drugs for patients with lung cancer, rare genetic porphyrias and heme-induced tissue injuries.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
ProteoValent Therapeutics
This company develops targeted protein degrader therapies for cancer and haematology patients.
Disc Medicine
This biopharmaceutical company develops novel therapeutic candidates to treat patients suffering from serious haematologic diseases by targeting red blood cell biology and iron homeostasis.
Forma Therapeutics
This company develops medicines for patients with sickle cell disease and rare blood disorders.
Vaderis Therapeutics
This company develops oral AKT inhibitor medicines for patients suffering from hereditary haemorrhagic telangiectasia and other rare vascular diseases.
BiPER Therapeutics
This company develops small molecule drugs targeting the BiP protein to treat gastrointestinal cancers and other pathological conditions in humans.
Veralox
This biotechnology company develops small-molecule therapeutics to treat inflammatory hematologic diseases and type 1 diabetes for patients with unmet medical needs.
Solu Therapeutics
This biotechnology company develops antibody-based medicines that target and eliminate disease-driving cells to treat patients with cancer and immunological disorders.
MyCural Therapeutics
This company develops small molecule drugs targeting the MYC oncoprotein to treat patients with aggressive, high-risk cancers.